Anoro Ellipta is the only LAMA/LABA with head-to-head data vs. a LAMA1,2,5,6 and vs. two LAMA/LABAs3,4

Discover the head-to-head data

Start strong by choosing Anoro Ellipta maintenance bronchodilator therapy for your symptomatic adult COPD patients

In a post hoc, pooled analysis of 3 RCTs at 24 weeks in patients not on maintenance therapy (for ≥30 days before screening):1,2

Anoro Ellipta demonstrated a 2.4x greater lung function improvement vs. tiotropium HandiHaler, with an extra 146mL improvement in trough FEV11,2

In two (out of three) individual 24-week RCTs in COPD patients not on maintenance therapy at the study screening visit:5,6

Anoro Ellipta significantly reduced rescue medication use vs. tiotropium HandiHaler5,6

In an 8-week open-label crossover study in patients not on maintenance therapy (for ≥2 weeks prior to randomisation):3

Anoro Ellipta demonstrated a 1.4x superior lung function improvement vs. Spiolto Respimat, with an extra 52mL improvement in trough FEV13

Anoro Ellipta was well tolerated and had a safety profile comparable to tiotropium HandiHaler1,5,6 and Spiolto Respimat3 in these studies/analyses

Find out more about Anoro Ellipta's head-to-head data:

Start with a LAMA/LABA

When your patients with COPD struggle with breathlessness, your choice of first-line maintenance therapy could make a difference.

ANORO ELLIPTA VS. LAMA 

Are all LAMA/LABAs the same?

Anoro Ellipta has head-to-head data
vs. Spiolto Respimat3 (a LAMA/LABA) and
vs. Bevespi Aerosphere4 (a LAMA/LABA).

ANORO ELLIPTA VS. LAMA/LABA 

Get started with Anoro Ellipta

References

  1. Maleki-Yazdi M et al. Adv Ther 2016; 33:2188–2199
  2. GSK data on file RF/UCV/0112/15
  3. Feldman G.J et al. Adv Ther 2017; 34:2518–2533
  4. Maltais F et al. Adv Ther 2019; 36(9):2434-2449
  5. Maleki-Yazdi MR et al. Respir Med 2014;108:1752–1760
  6. Decramer M et al. Lancet Respir Med 2014;2:472–486.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.

Innoviva Logo

PM-GB-UCV-WCNT-200036 May 2021